425: Freenome CRC Blood Test Shows Improved Precancerous Lesion Detection

Freenome announces updated SimpleScreen CRC blood test met all primary and secondary endpoints in a pivotal clinical validation study, showing significant improvements in detecting advanced precancerous lesions.

Summary

• Freenome Holdings, Inc. announced positive top-line results from a clinical validation study for its updated SimpleScreen CRC blood-based colorectal cancer screening test.
• The updated test successfully met all primary and secondary endpoints, demonstrating significant performance improvements, particularly in detecting advanced precancerous lesions (APLs) with high-grade dysplasia (HGD).
• The study showed 18.2% sensitivity for APLs and 41.9% sensitivity for APLs with HGD, which are the highest reported for a non-invasive screening blood test in a prospective registrational pivotal clinical study.
• Sensitivity for detecting colorectal cancer (CRC) was 80.4%, including 52% of Stage I cases, with a specificity for no findings on colonoscopy of 90%.
• Modeling suggests these improvements could lead to 1,582 additional life-years gained, 426 fewer CRC cases, and 143 fewer CRC deaths per 100,000 individuals screened compared to the first-generation test.
• Freenome submitted a Premarket Approval (PMA) application to the FDA in August 2025 for the first-generation test and plans to submit a supplemental PMA for the next-generation test.
• A commercial collaboration with Abbott, initiated in August 2025, aims to bring SimpleScreen CRC to market, with Abbott exclusively commercializing the test upon FDA approval.
• The collaboration includes a potential $70 million milestone payment tied to FDA approval of the next-generation test and successful technology transfer.
• Freenome is also developing a multi-cancer product combining SimpleScreen CRC with its SimpleScreen Lung test.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to the successful clinical validation and improved performance metrics of the SimpleScreen CRC test, indicating progress towards market approval and commercialization.

Positives

• The updated SimpleScreen CRC test met all primary and secondary endpoints in its pivotal clinical validation study.
• Demonstrated significant improvement in detecting advanced precancerous lesions (APLs) with 18.2% sensitivity.
• Achieved 41.9% sensitivity for detecting APLs with high-grade dysplasia (HGD), the highest reported for a non-invasive blood test in a similar study.
• High sensitivity for detecting CRC at 80.4%, including 52% of Stage I cases.
• Specificity for no findings on colonoscopy was 90%.
• Projected to increase life-years gained by 7.7%, prevent 9.5% more CRC cases, and prevent 9.5% more CRC deaths per 100,000 individuals screened compared to the first-generation test.
• Successful clinical validation marks a major milestone for Freenome's mission in early cancer detection.
• Commercial collaboration with Abbott to bring the test to market is progressing.
• Potential $70 million milestone payment from Abbott upon FDA approval and technology transfer.

Negatives

• Sensitivity for detecting APLs (18.2%) and APLs with HGD (41.9%) is still lower than desired for widespread adoption as a standalone screening tool, though improved.
• The FDA is expected to complete its review of the first-generation test in mid-2026, with no specific timeline for the next-generation test's review.
• The $70 million milestone payment is contingent on FDA approval of the next-generation test and successful technology transfer, introducing uncertainty.
• The company faces ongoing risks related to product development, regulatory approvals, commercialization, and competition.

Risks

• Uncertainty regarding the outcomes of Freenome's product development activities and the timing of clinical trial initiations, completions, and data readouts.
• Risks associated with obtaining potential FDA approval for Freenome's tests and products.
• Challenges in commercializing its product candidates and ability to negotiate and enter into new definitive agreements on favorable terms.
• The impact of competing product candidates on Freenome's business.
• Intellectual property-related claims.
• Freenome's ability to attract and retain qualified personnel.
• Freenome's ability to source the raw materials for its product candidates.
• Risks related to the proposed business combination with Perceptive Capital Solutions Corp., including the inability to successfully or timely consummate the transaction.
• Changes in domestic and foreign business, market, financial, political, and legal conditions.
• Global economic and political conditions.
• The occurrence of any event, change or other circumstance that could give rise to the termination of the Business Combination Agreement.

Future Outlook

Freenome intends to submit a supplemental PMA to the FDA for the next-generation SimpleScreen CRC test. The company is also advancing its pipeline of single- and multi-cancer tests, aiming to match blood-based screening tests to individual cancer relevance based on health profiles and leveraging its multiomics platform for additional indications. The business combination with Perceptive Capital Solutions Corp. is expected to result in PCSC being renamed Freenome, Inc. (New Freenome) upon closing.

Management Comments

• "The sensitivity results for APL and APL with HGD demonstrated in this study are the highest reported to date for any non-invasive screening blood test in a prospective registrational pivotal clinical study."
• "With the improved detection of APLs and HGD, our published model suggests that the updated test would result in 7.7% more life-years gained, 9.5% more cases of cancer prevented, and 9.5% more cancer deaths prevented, compared to the first-generation CRC test version."
• "This study marks a major milestone in our mission to advance blood-based colorectal cancer screening. The significant improvement in detecting precancerous lesions demonstrates the critical role our SimpleScreen CRC platform can play in early detection and prevention of colon cancer."
• "With millions of eligible Americans still not getting screened, expanding access to accurate, non-invasive screening options that patients are more likely to complete has never been more important."
• "These results strengthen our confidence in the role blood-based colorectal cancer screening can play in expanding screening. Combined with Abbott's preferred, guideline-supported screening option, we're uniquely positioned to offer healthcare providers and patients a differentiated colorectal cancer screening portfolio built on innovation, performance and choice—with one goal in mind: helping more people get screened."

Industry Context

StockSavvy.ai notes that Freenome's announcement positions it as a key player in the rapidly evolving field of early cancer detection, specifically for colorectal cancer. The emphasis on improved detection of precancerous lesions is critical, as this is a major unmet need in current screening methods. The collaboration with Abbott, a major diagnostics player, suggests a strategic move towards broader market penetration. The company's multiomics approach and AI/ML integration align with industry trends towards personalized and more accurate diagnostic tools.

Comparison to Industry Standards

• The reported sensitivity for APLs (18.2%) and APLs with HGD (41.9%) for the updated SimpleScreen CRC test are stated as the highest reported to date for any non-invasive screening blood test in a prospective registrational pivotal clinical study.
• The sensitivity for CRC detection (80.4%) is comparable to other leading screening methods, though specificity (90%) is a key metric for comparison against colonoscopy.
• The projected benefits (7.7% more life-years gained, 9.5% more cases prevented, 9.5% more deaths prevented) are modeled against the first-generation test, indicating an improvement in potential population health outcomes.
• The company aims to match the performance of certain stool-based CRC screening tests, which are a current standard for non-invasive screening, while offering potentially higher adherence.

Stakeholder Impact

• Shareholders: Potential positive impact from the advancement of a key product, potential milestone payments, and the ongoing business combination, which could lead to increased company valuation.
• Patients: Potential for improved access to early colorectal cancer screening through a non-invasive blood test, leading to earlier detection and better health outcomes.
• Healthcare Providers: Opportunity to offer a new, potentially more convenient screening option for patients who may not undergo colonoscopies.
• Abbott: Strengthens its diagnostics portfolio and potential for revenue generation through exclusive commercialization of SimpleScreen CRC.

Next Steps

• Submit a supplemental PMA to the FDA for the next-generation SimpleScreen CRC test.
• Commercialize SimpleScreen CRC through Abbott upon FDA approval.
• Continue R&D program with Abbott focused on improving assay performance.
• Develop and commercialize multi-cancer products.
• Complete the business combination with Perceptive Capital Solutions Corp.

Key Dates

Recommendation

The results are positive and demonstrate significant progress in Freenome's core technology for early cancer detection. However, the path to full FDA approval for the next-generation test and successful commercialization still involves regulatory hurdles, market adoption challenges, and ongoing R&D. The ongoing business combination also introduces a layer of complexity. Therefore, a 'hold' recommendation is appropriate, pending further clarity on regulatory timelines and commercial execution, while acknowledging the strong technological advancements.

Keywords

Freenome, SimpleScreen CRC, Colorectal Cancer, Blood Test, Early Cancer Detection, Clinical Validation, Advanced Precancerous Lesions, High-Grade Dysplasia, FDA, Premarket Approval, Abbott, Perceptive Capital Solutions Corp, Business Combination